Status of research and development of vaccines for chikungunya

Claire Smalley, Jesse H. Erasmus, Charles B. Chesson, David Beasley

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.

Original languageEnglish (US)
Pages (from-to)2976-2981
Number of pages6
JournalVaccine
Volume34
Issue number26
DOIs
StatePublished - Jun 3 2016

Fingerprint

Chikungunya virus
research and development
Vaccines
vaccines
Research
Disease Outbreaks
Alphavirus
burden of disease
vaccine development
chronic diseases
human diseases
income
Chronic Disease
Mortality

Keywords

  • Alphavirus
  • Chikungunya
  • Emerging disease
  • Polyarthralgia
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Status of research and development of vaccines for chikungunya. / Smalley, Claire; Erasmus, Jesse H.; Chesson, Charles B.; Beasley, David.

In: Vaccine, Vol. 34, No. 26, 03.06.2016, p. 2976-2981.

Research output: Contribution to journalArticle

Smalley, Claire ; Erasmus, Jesse H. ; Chesson, Charles B. ; Beasley, David. / Status of research and development of vaccines for chikungunya. In: Vaccine. 2016 ; Vol. 34, No. 26. pp. 2976-2981.
@article{a1a74ca3022c4015bd22d582a918361c,
title = "Status of research and development of vaccines for chikungunya",
abstract = "Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.",
keywords = "Alphavirus, Chikungunya, Emerging disease, Polyarthralgia, Vaccine",
author = "Claire Smalley and Erasmus, {Jesse H.} and Chesson, {Charles B.} and David Beasley",
year = "2016",
month = "6",
day = "3",
doi = "10.1016/j.vaccine.2016.03.076",
language = "English (US)",
volume = "34",
pages = "2976--2981",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",

}

TY - JOUR

T1 - Status of research and development of vaccines for chikungunya

AU - Smalley, Claire

AU - Erasmus, Jesse H.

AU - Chesson, Charles B.

AU - Beasley, David

PY - 2016/6/3

Y1 - 2016/6/3

N2 - Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.

AB - Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.

KW - Alphavirus

KW - Chikungunya

KW - Emerging disease

KW - Polyarthralgia

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84962439158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962439158&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.03.076

DO - 10.1016/j.vaccine.2016.03.076

M3 - Article

VL - 34

SP - 2976

EP - 2981

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -